Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "中国卫通2025年12月第一周走势预测"

Looking for quality documents?
external link icon
Repligen Launches the CTech™ SoloVPE® PLUS System
Next-Generation At-Line Concentration Measurement for Bioprocessing WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its CTech™ SoloVPE ® PLUS System, the most advanced UV-based Variable Pathlength Technology system now available to biopharmaceutical manufacturers. The SoloVPE PLUS System is engineered to offer unparalleled accuracy, speed, and ease-of-use for at-line ultraviolet-visible (UV-Vis) concentration measurement in complex biological production workflows, from process development scale through cGMP manufacturing. As the bioprocess industry shifts toward higher drug concentration formulations to improve efficiency and reduce production costs, there has been a growing need for faster, more reliable and more accurate analytical tools. The SoloVPE PLUS System addresses this need, utilizing variable pathlength spectroscopy to deliver
external link icon
Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer
WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed 20+ year industry veteran Olivier Loeillot to the newly created position of President and Chief Commercial Officer (CCO), effective immediately. Mr. Loeillot served a combined 12 years with Cytiva (a Danaher company) and GE Healthcare Life Sciences. In his most recent role at Cytiva, he served as Bioprocess President from 2018 to 2022, overseeing the overall Bioprocess portfolio from cell culture media to purification resins and including process equipment, single-use technologies and enterprise solutions. Prior to Cytiva, he worked for a combined 12 years with Lonza, advancing to Vice President Sales, Lonza Custom Manufacturing. Mr. Loeillot joins Repligen from his most recent role as Chief Executive Officer (CEO) of Ascensus Specialties, a manufacturer of specialty chemicals for use in the
external link icon
Repligen to Present at 35th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 04, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at the 35 th Annual J.P. Morgan Healthcare conference being held January 9-12 at the Westin St. Francis in San Francisco.  Tony J. Hunt, President and Chief Executive Officer, will make a formal presentation on Thursday, January 12, at 11:00 a.m. PST.
A live webcast of the presentation will be accessible through the Investor Events section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a bioprocessing company focused on the development, manufacture and commercialization of highly innovative products used to improve the process of manufacturing biologic drugs. Our bioprocessing products are sold to major life sciences companies,
external link icon
Repligen to Present at 2015 Leerink Global Healthcare Conference
WALTHAM, Mass., Feb. 4, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that the Company will present at the 2015 Leerink Global Healthcare Conference to be held February 11-12 at the Waldorf Astoria hotel in New York. Management is scheduled to participate in an analyst-moderated "fireside chat" with investors at 2:40 p.m. EST on Thursday, February 12, 2015. A live audio webcast of this discussion will be accessible through the Investor Events section of Company's website. A replay of the webcast will also be accessible for a period of time following the event. About Repligen Corporation Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical
news icon
Repligen Appoints Jacob Johnson As Vice President Investor Relations
news icon
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices
news icon
Yokogawa and Repligen Partner to Enhance Process Analytical Technology
external link icon
Repligen Reports Second Quarter 2013 Financial Results
- Product Revenue Grows 12% for the Quarter on Record Bioprocessing Sales - - Net Income Grows 189% to $4.5 Million - - Earnings Conference Call and Webcast Today at 9:00 a.m. EDT - WALTHAM, Mass., Aug. 1, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today reported financial results for the second quarter ended June 30, 2013. Below are the Company's financial and business highlights for the second quarter of 2013, financial guidance for the year and dial-in numbers for today's conference call. Second Quarter 2013 Financial Highlights Bioprocessing product revenue for the second quarter of 2013 reached a record $13.0 million, an increase of 12% over the second quarter of 2012.
  Total revenue for the second quarter of 2013 was $17.5 million, an increase of 13% over the second quarter of 2012.
  Bioprocessing product gross profit margin was 59% for the second quarter of 2013, compared with 37% during the second quarter of 2012.
  Net income
external link icon
Repligen Appoints Jacob Johnson As Vice President Investor Relations
WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the investor relations team’s engagement with the investment community, reporting to the company’s Chief Financial Officer, Jason K. Garland. Most recently, Mr. Johnson served as Managing Director, Research Analyst at Stephens Inc., where he followed the life sciences tools and pharma services sector. Mr. Garland commented, “Jacob is a terrific addition to the Repligen team, bringing a broad understanding of the bioprocessing tools space, the markets we serve and the growth drivers for our industry and the company. Jacob has covered Repligen as a research analyst since 2019; his immediate familiarity with the company and our technologies will enable Jacob to seamlessly engage with the investor audience and pick up leadership of the IR function.” Mr. Garland added, “While
external link icon
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices
Portfolio includes PAT devices for real-time process monitoring, control and analysis WALTHAM, Mass. and BOSTON, March 04, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc . (Nasdaq: MASS), a pioneer in purpose-built handheld and desktop devices for chemical analysis, announce that Repligen has purchased 908 Devices’ desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices remains focused on the growth of its newly expanded handheld device portfolio for vital health and safety applications. The addition of these desktop assets complements and strengthens Repligen’s differentiated PAT portfolio that provides its biopharmaceutical and CDMO customers with actionable insights to optimize development processes and improve manufacturing efficiencies. Products acquired from 908 Devices include MAVERICK and MAVEN for real-time